Analysts Split on Health In Tech as Insurance Tech Firm Stays Unprofitable
Health In Tech, Inc. (NASDAQ: HIT) is drawing a mixed but active round of coverage from Wall Street research desks, with Maxim Group reaffirming a "Buy" rating and a $3.00 price target even as its
